2019 Biennial ATTR (Familial) Meeting

From October 25-27, 2019, I was able to attend this meeting in Chicago, arranged by Amyloidosis Support Groups. The goal of the conference was to inform and share information about amyloidosis, current and future treatments, clinical trials and research updates....

November 16 webinar recording now available!

Thank you to all who were able to join us on November 16 for the Unfolding hATTR: Cardiac Amyloidosis presentation with Dr. Diego Delgado. In case you missed it, you can listen to a recording of the webinar here: If you have any future webinar topic...

NOVEMBER 16 WEBINAR – You’re Invited!

Unfolding hATTR: Update on Cardiac Amyloidosis Are you or a loved one living with hereditary ATTR (hATTR) amyloidosis? On behalf of Hereditary Amyloidosis Canada, we’d like to invite you to our first webinar for Canadian patients, caregivers and family members to help...

Onpattro® (patisiran) is now approved in Canada

Alnylam Pharmaceuticals, Inc. Announce Health Canada’s Approval of Onpattro® (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. To learn more, please...

Access to Treatment in Québec – Have Your Say

L’INESSS in Québec is evaluating inotersen (Tegsedi – Akcea Therapeutics Canada) a treatment for adults with hATTR amyloidosis polyneuropathy. L’INESSS does this evaluation to determine whether to recommend the drug for reimbursement by the Québec government....